APO-IMATINIB

APO-IMATINIB is indicated for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase.

APO-IMATINIB is also indicated for the treatment of adult patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase or in chronic phase (after failure of interferon-alpha therapy).

APO-IMATINIB is also indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

APO-IMATINIB is also indicated for the treatment of adult patients with relapsed or refractory Ph+ ALL as single agent.

APO-IMATINIB is also indicated for the treatment of adult patients with myelodysplastic/Myeloproliferative diseases (MDS/MPD) associated with plateletderived growth factor receptor (PDGFR) gene re-arrangements.

APO-IMATINIB is also indicated for the treatment of adult patients with aggressive subtypes of systemic mastocytosis (ASM and SMAHNMD1) without the D816V c-Kit mutation. If c-Kit mutational status in patients with ASM or SM-AHNMD1 is not known or unavailable, treatment with APO-IMATINIB may be considered if there is no satisfactory response to other therapies.

APO-IMATINIB is also indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement.